{
    "id": 17238,
    "fullName": "FGFR1OP2 - FGFR1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR1OP2-FGFR1 results from the fusion of FGFR1OP2 and FGFR1, demonstrating constitutive kinase activity (PMID: 21745565).",
            "references": [
                {
                    "id": 4453,
                    "pubMedId": 21745565,
                    "title": "The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21745565"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 26127,
        "geneSymbol": "FGFR1OP2",
        "terms": [
            "FGFR1OP2",
            "HSPC123-like",
            "WIT3.0"
        ]
    },
    "variant": "FGFR1OP2 - FGFR1",
    "createDate": "01/26/2016",
    "updateDate": "01/26/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2260,
                "geneSymbol": "FGFR1",
                "terms": [
                    "FGFR1",
                    "bFGF-R-1",
                    "BFGFR",
                    "CD331",
                    "CEK",
                    "ECCL",
                    "FGFBR",
                    "FGFR-1",
                    "FLG",
                    "FLT-2",
                    "FLT2",
                    "HBGFR",
                    "HH2",
                    "HRTFDS",
                    "KAL2",
                    "N-SAM",
                    "OGD"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 9135,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a leukemic cell line harboring FGFR1OP2-FGFR1 (PMID: 22875613) demonstrated sensitivity to E7090 in culture, which resulted in decreased cell viability (PMID: 27535969).",
            "molecularProfile": {
                "id": 17524,
                "profileName": "FGFR1OP2 - FGFR1"
            },
            "therapy": {
                "id": 4911,
                "therapyName": "E7090",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5786,
                    "pubMedId": 22875613,
                    "title": "Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22875613"
                },
                {
                    "id": 6928,
                    "pubMedId": 27535969,
                    "title": "E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535969"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10013,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 decreased Myc expression, induced cell-cycle arrest, and inhibited growth of a hematologic cancer cell line harboring FGFR1OP2-FGFR1 in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 17524,
                "profileName": "FGFR1OP2 - FGFR1"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10024,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 decreased Myc expression, induced cell-cycle arrest, and inhibited growth of a hematologic cancer cell line harboring FGFR1OP2-FGFR1 in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 17524,
                "profileName": "FGFR1OP2 - FGFR1"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6184,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation and induced apoptosis in an acute myeloid leukemia cell line harboring FGFR1OP2-FGFR1 in culture (PMID: 22875613).",
            "molecularProfile": {
                "id": 17524,
                "profileName": "FGFR1OP2 - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5786,
                    "pubMedId": 22875613,
                    "title": "Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22875613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8004,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited FGFR1 signaling and viability in leukemia cells harboring FGFR1OP2-FGFR1 in culture (PMID: 21482694).",
            "molecularProfile": {
                "id": 17524,
                "profileName": "FGFR1OP2 - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3255,
                    "pubMedId": 21482694,
                    "title": "Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21482694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17524,
            "profileName": "FGFR1OP2 - FGFR1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}